Compare $BCRX vs $VCEL | Chartloom

Compare

$BCRX vs $VCEL

BioCryst Pharmaceuticals Inc · Vericel Corp

BCRX

BioCryst Pharmaceuticals Inc

VCEL

Vericel Corp

Compare $BCRX vs $VCEL

Comparing BioCryst Pharmaceuticals Inc and Vericel Corp

BCRXBioCryst Pharmaceuticals Inc

VCELVericel Corp

BCRXBioCryst Pharmaceuticals Inc

Market cap

$2.17B

P/E (TTM)

—

Forward P/E (NTM)

16.67x

Forward P/S (NTM)

3.13x

Rev growth (TTM)

68.7%

YTD performance

14.0%

52W performance

17.4%

FCF yield

17.9%

VCELVericel Corp

Market cap

$2.05B

P/E (TTM)

86.61x

Forward P/E (NTM)

55.49x

Forward P/S (NTM)

5.56x

Rev growth (TTM)

23.0%

YTD performance

12.6%

52W performance

17.5%

FCF yield

3.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BCRX

VCEL

Detailed metrics comparison

BCRX

BioCryst Pharmaceuticals Inc

VCEL

Vericel Corp

Market Cap

BCRX$2.17B

VCEL$2.05B

Enterprise Value

BCRX$2.84B

VCEL$1.92B

Price

BCRX$8.55

VCEL$40.10

P/E Ratio

BCRXN/A

VCEL86.61x

P/S Ratio

BCRX2.31x

VCEL6.69x

EV/Sales

BCRX3.02x

VCEL6.28x

EV/EBITDA

BCRX6.85x

VCEL58.45x

P/B Ratio

BCRX62.13x

VCEL5.56x

P/FCF Ratio

BCRX5.59x

VCEL33.21x

EV/FCF

BCRX7.32x

VCEL31.19x

PEG Ratio

BCRXN/A

VCEL0.32x

Forward P/E (NTM)

BCRX16.67x

VCEL55.49x

Forward P/S (NTM)

BCRX3.13x

VCEL5.56x

Revenue (TTM)

BCRX$941M

VCEL$306M

Revenue Growth (YoY)

BCRX68.7%

VCEL23.0%

Forward Rev Growth

BCRX3.9%

VCEL16.9%

Gross Margin (TTM)

BCRX97.8%

VCEL74.6%

Operating Margin (TTM)

BCRX0.0%

VCEL6.0%

EBITDA Margin (TTM)

BCRX41.1%

VCEL10.2%

Net Margin (TTM)

BCRX-40.9%

VCEL7.9%

FCF Margin (TTM)

BCRX41.3%

VCEL20.1%

Net Income (TTM)

BCRX$-385M

VCEL$24M

FCF (TTM)

BCRX$388M

VCEL$62M

EPS (TTM)

BCRX-$1.45

VCEL$0.46

ROE (TTM)

BCRX-32882.0%

VCEL6.9%

ROA (TTM)

BCRX-7758.0%

VCEL5.0%

ROIC (TTM)

BCRX-10666.0%

VCEL6.9%

Cash

BCRX$155M

VCEL$125M

Debt

BCRX$824M

VCEL$596K

Net Cash/Debt

BCRX$-669M

VCEL$125M

Current Ratio (TTM)

BCRX2.32x

VCEL5.04x

Quick Ratio (TTM)

BCRX2.22x

VCEL4.69x

Debt/Equity (TTM)

BCRX2.26x

VCEL0.00x

Debt/Assets (TTM)

BCRX0.0%

VCEL0.0%

Interest Coverage (TTM)

BCRXN/A

VCELN/A

Net Debt/EBITDA (TTM)

BCRX0.00x

VCEL0.00x

Beta

BCRX0.54

VCEL1.06

52W Performance

BCRX17.4%

VCEL17.5%

YTD Performance

BCRX14.0%

VCEL12.6%

% from 52W High

BCRX-23.8%

VCEL-18.7%

% from 52W Low

BCRX42.5%

VCEL38.5%

Asset Turnover (TTM)

BCRX1.90x

VCEL0.63x

FCF Yield (TTM)

BCRX17.9%

VCEL3.0%

Earnings Yield (TTM)

BCRX-17.7%

VCEL1.2%

Dividend Yield (TTM)

BCRXN/A

VCELN/A

Rule of 40

BCRX110.0

VCEL43.1

EV/GP/RG

BCRX0.74

VCEL0.39

Ticker research

View BCRX research View VCEL research

Metric	BCRX BioCryst Pharmaceuticals Inc	VCEL Vericel Corp
Market & Valuation
Market Cap	$2.17B	$2.05B
Enterprise Value	$2.84B	$1.92B
Price	$8.55	$40.10
P/E Ratio	N/A	86.61x
P/S Ratio	2.31x	6.69x
EV/Sales	3.02x	6.28x
EV/EBITDA	6.85x	58.45x
P/B Ratio	62.13x	5.56x
P/FCF Ratio	5.59x	33.21x
EV/FCF	7.32x	31.19x
PEG Ratio	N/A	0.32x
Forward P/E (NTM)	16.67x	55.49x
Forward P/S (NTM)	3.13x	5.56x
Revenue & Growth
Revenue (TTM)	$941M	$306M
Revenue Growth (YoY)	68.7%	23.0%
Forward Rev Growth	3.9%	16.9%
Profitability
Gross Margin (TTM)	97.8%	74.6%
Operating Margin (TTM)	0.0%	6.0%
EBITDA Margin (TTM)	41.1%	10.2%
Net Margin (TTM)	-40.9%	7.9%
FCF Margin (TTM)	41.3%	20.1%
Net Income (TTM)	$-385M	$24M
FCF (TTM)	$388M	$62M
EPS (TTM)	-$1.45	$0.46
ROE (TTM)	-32882.0%	6.9%
ROA (TTM)	-7758.0%	5.0%
ROIC (TTM)	-10666.0%	6.9%
Financial Health
Cash	$155M	$125M
Debt	$824M	$596K
Net Cash/Debt	$-669M	$125M
Current Ratio (TTM)	2.32x	5.04x
Quick Ratio (TTM)	2.22x	4.69x
Debt/Equity (TTM)	2.26x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.54	1.06
52W Performance	17.4%	17.5%
YTD Performance	14.0%	12.6%
% from 52W High	-23.8%	-18.7%
% from 52W Low	42.5%	38.5%
Efficiency & Yields
Asset Turnover (TTM)	1.90x	0.63x
FCF Yield (TTM)	17.9%	3.0%
Earnings Yield (TTM)	-17.7%	1.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	110.0	43.1
EV/GP/RG	0.74	0.39
Ticker research	View BCRX research	View VCEL research

Valuation

P/E Ratio

VCEL

86.61x

P/S Ratio

BCRX

2.31x

VCEL

6.69x

EV/FCF

BCRX

7.32x

VCEL

31.19x

Growth & revenue

Revenue Growth TTM

BCRX

68.7%

VCEL

23.0%

Forward Revenue Growth

VCEL

16.9%

BCRX

3.9%

Profitability & performance

Gross Margin

BCRX

97.8%

VCEL

74.6%

ROE

VCEL

6.9%

BCRX

-32882.0%

FCF Yield %

BCRX

17.9%

VCEL

3.0%

52-Week Performance

VCEL

17.5%

BCRX

17.4%

Detailed metrics comparison

BCRX

BioCryst Pharmaceuticals Inc

VCEL

Vericel Corp

Market Cap

BCRX$2.17B

VCEL$2.05B

Enterprise Value

BCRX$2.84B

VCEL$1.92B

Price

BCRX$8.55

VCEL$40.10

P/E Ratio

BCRXN/A

VCEL86.61x

P/S Ratio

BCRX2.31x

VCEL6.69x

EV/Sales

BCRX3.02x

VCEL6.28x

EV/EBITDA

BCRX6.85x

VCEL58.45x

P/B Ratio

BCRX62.13x

VCEL5.56x

P/FCF Ratio

BCRX5.59x

VCEL33.21x

EV/FCF

BCRX7.32x

VCEL31.19x

PEG Ratio

BCRXN/A

VCEL0.32x

Forward P/E (NTM)

BCRX16.67x

VCEL55.49x

Forward P/S (NTM)

BCRX3.13x

VCEL5.56x

Revenue (TTM)

BCRX$941M

VCEL$306M

Revenue Growth (YoY)

BCRX68.7%

VCEL23.0%

Forward Rev Growth

BCRX3.9%

VCEL16.9%

Gross Margin (TTM)

BCRX97.8%

VCEL74.6%

Operating Margin (TTM)

BCRX0.0%

VCEL6.0%

EBITDA Margin (TTM)

BCRX41.1%

VCEL10.2%

Net Margin (TTM)

BCRX-40.9%

VCEL7.9%

FCF Margin (TTM)

BCRX41.3%

VCEL20.1%

Net Income (TTM)

BCRX$-385M

VCEL$24M

FCF (TTM)

BCRX$388M

VCEL$62M

EPS (TTM)

BCRX-$1.45

VCEL$0.46

ROE (TTM)

BCRX-32882.0%

VCEL6.9%

ROA (TTM)

BCRX-7758.0%

VCEL5.0%

ROIC (TTM)

BCRX-10666.0%

VCEL6.9%

Cash

BCRX$155M

VCEL$125M

Debt

BCRX$824M

VCEL$596K

Net Cash/Debt

BCRX$-669M

VCEL$125M

Current Ratio (TTM)

BCRX2.32x

VCEL5.04x

Quick Ratio (TTM)

BCRX2.22x

VCEL4.69x

Debt/Equity (TTM)

BCRX2.26x

VCEL0.00x

Debt/Assets (TTM)

BCRX0.0%

VCEL0.0%

Interest Coverage (TTM)

BCRXN/A

VCELN/A

Net Debt/EBITDA (TTM)

BCRX0.00x

VCEL0.00x

Beta

BCRX0.54

VCEL1.06

52W Performance

BCRX17.4%

VCEL17.5%

YTD Performance

BCRX14.0%

VCEL12.6%

% from 52W High

BCRX-23.8%

VCEL-18.7%

% from 52W Low

BCRX42.5%

VCEL38.5%

Asset Turnover (TTM)

BCRX1.90x

VCEL0.63x

FCF Yield (TTM)

BCRX17.9%

VCEL3.0%

Earnings Yield (TTM)

BCRX-17.7%

VCEL1.2%

Dividend Yield (TTM)

BCRXN/A

VCELN/A

Rule of 40

BCRX110.0

VCEL43.1

EV/GP/RG

BCRX0.74

VCEL0.39

Ticker research

View BCRX research View VCEL research

Metric	BCRX BioCryst Pharmaceuticals Inc	VCEL Vericel Corp
Market & Valuation
Market Cap	$2.17B	$2.05B
Enterprise Value	$2.84B	$1.92B
Price	$8.55	$40.10
P/E Ratio	N/A	86.61x
P/S Ratio	2.31x	6.69x
EV/Sales	3.02x	6.28x
EV/EBITDA	6.85x	58.45x
P/B Ratio	62.13x	5.56x
P/FCF Ratio	5.59x	33.21x
EV/FCF	7.32x	31.19x
PEG Ratio	N/A	0.32x
Forward P/E (NTM)	16.67x	55.49x
Forward P/S (NTM)	3.13x	5.56x
Revenue & Growth
Revenue (TTM)	$941M	$306M
Revenue Growth (YoY)	68.7%	23.0%
Forward Rev Growth	3.9%	16.9%
Profitability
Gross Margin (TTM)	97.8%	74.6%
Operating Margin (TTM)	0.0%	6.0%
EBITDA Margin (TTM)	41.1%	10.2%
Net Margin (TTM)	-40.9%	7.9%
FCF Margin (TTM)	41.3%	20.1%
Net Income (TTM)	$-385M	$24M
FCF (TTM)	$388M	$62M
EPS (TTM)	-$1.45	$0.46
ROE (TTM)	-32882.0%	6.9%
ROA (TTM)	-7758.0%	5.0%
ROIC (TTM)	-10666.0%	6.9%
Financial Health
Cash	$155M	$125M
Debt	$824M	$596K
Net Cash/Debt	$-669M	$125M
Current Ratio (TTM)	2.32x	5.04x
Quick Ratio (TTM)	2.22x	4.69x
Debt/Equity (TTM)	2.26x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.54	1.06
52W Performance	17.4%	17.5%
YTD Performance	14.0%	12.6%
% from 52W High	-23.8%	-18.7%
% from 52W Low	42.5%	38.5%
Efficiency & Yields
Asset Turnover (TTM)	1.90x	0.63x
FCF Yield (TTM)	17.9%	3.0%
Earnings Yield (TTM)	-17.7%	1.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	110.0	43.1
EV/GP/RG	0.74	0.39
Ticker research	View BCRX research	View VCEL research